KIDS - NASDAQ
OrthoPediatrics Corp.
$18.15
+8.0%OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
At a Glance
Live SnapshotOrthoPediatrics Corp. Management Team
Mr. Fred L. Hite
Chief Financial Officer, Principal Financial & Accounting Officer, Chief Operating Officer and Director
Compensation
$881,882
Mr. Mark C. Throdahl
Executive Chairman
Compensation
$45,000
Mr. Daniel J. Gerritzen J.D.
Executive Vice President of Legal, General Counsel & Secretary
Compensation
$559,908
Mr. Kevin L. Unger CHE, MBA/MSHA
President of Enabling Technologies
Compensation
$22,500
Mr. Gregory A. Odle
President of Scoliosis
Compensation
$560,942
Mr. Joseph W. Hauser
President of Trauma, Deformity Correction & OPSB
Compensation
$609,186
Mr. David R. Bailey
President, Chief Executive Officer & Director
Compensation
$963,117
Mr. Mark Karshner
Senior Vice President of International Sales
Ray Garrison
Senior Vice President of Quality & Regulatory and Clinical
OrthoPediatrics Corp. Insider Positioning
During the last 12 months, insiders have purchased $99K and sold $1.00M worth of KIDS shares, resulting in $905K of net selling activity.
3 Months
0
0.00
58.2K
1.00M
-1.0M
-$1.00M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
5.1K
98.53K
0
0.00
+99K
+$99K
Top Buyers
Hite Fred
Director, Officer: Coo And Cfo
$99K
Top Sellers
Bailey David R
Director, Officer: President And Ceo
$337K
Hite Fred
Director, Officer: Coo And Cfo
$224K
Gerritzen Daniel J
Officer: General Counsel And Secretary
$149K
Hauser Joseph W
Officer: Pres. Trauma & Def. Correction
$148K
Odle Gregory A
Officer: President Of Scoliosis
$145K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $905K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
KIDS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 02, 2025 | April 02, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 08, 2024 | April 08, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | April 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 15, 2022 | April 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 16, 2021 | April 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 17, 2020 | April 15, 2020 | 2020 | |
DEF 14A DEF 14A 2018 N/A | April 15, 2019 | December 31, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | June 20, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.